Takeda Pharmaceutical (TAK) Competitors

Sanofi (NASDAQ:SNY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Do insiders & institutionals have more ownership in SNY or TAK?

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Do analysts rate SNY or TAK?

Sanofi currently has a consensus target price of $62.00, suggesting a potential upside of 30.72%. Given Sanofi's stronger consensus rating and higher probable upside, analysts clearly believe Sanofi is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	3 Strong Buy rating(s)	3.13
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is SNY or TAK a better dividend stock?

Sanofi pays an annual dividend of $1.60 per share and has a dividend yield of 3.4%. Takeda Pharmaceutical pays an annual dividend of $0.55 per share and has a dividend yield of 3.8%. Sanofi pays out 38.5% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 183.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Which has more risk and volatility, SNY or TAK?

Sanofi has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500.

Which has better earnings and valuation, SNY or TAK?

Sanofi has higher revenue and earnings than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$44.46B	2.62	$6.02B	$4.16	11.40
Takeda Pharmaceutical	$30.09B	1.52	$712.33M	$0.30	47.95

Does the media favor SNY or TAK?

In the previous week, Sanofi had 41 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 44 mentions for Sanofi and 3 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.98 beat Sanofi's score of 0.52 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	11 Very Positive mention(s)	8 Positive mention(s)	19 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive
Takeda Pharmaceutical	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is SNY or TAK more profitable?

Sanofi has a net margin of 21.47% compared to Takeda Pharmaceutical's net margin of 3.20%. Sanofi's return on equity of 16.86% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	21.47%	16.86%	9.63%
Takeda Pharmaceutical	3.20%	10.50%	5.10%

Summary

Sanofi beats Takeda Pharmaceutical on 16 of the 19 factors compared between the two stocks.